Search results for "mRNA vaccines"

showing 6 items of 6 documents

Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune res…

2021

Significance Vaccines profit from the addition of adjuvants to better and more specifically initiate, amplify, and shape immune responses. Although the number of adjuvant candidates has steadily increased, peaking in the current SARS-CoV-2 pandemic, little is known about their inherent mode of action. Using human blood immune cells, we established a multilayer method to systematically assess the adjuvants’ effects on innate and adaptive immune cells. By employing a multiplex analysis with cells from 30 different donors, we determined important patterns of adjuvant function. Moreover, we demonstrate correlates of an antiviral immune response using a Toll-like receptor 7/8 ligand adjuvant and…

AdultMaleAdolescentT-LymphocytesMonophosphoryl Lipid ALipid Achemistry.chemical_compoundImmunology and InflammationImmune systemAdjuvants ImmunologicInterferonTLRmedicineHumansprimary human cellsAgedImmunity CellularToll-like receptorMultidisciplinarySARS-CoV-2ChemistryToll-Like ReceptorsImidazolesCOVID-19Dendritic CellsTLR7biochemical phenomena metabolism and nutritionBiological SciencesMiddle AgedCOVID-19 ; TLR ; primary human cells ; adjuvants ; mRNA vaccines420Cell biologymRNA vaccinesLipid AadjuvantsTLR4[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleResiquimodmedicine.drugProceedings of the National Academy of Sciences
researchProduct

Cutaneous and Allergic reactions due to COVID‐19 vaccinations: A review

2021

ABSTRACT Introduction The pandemic caused by the novel coronavirus disease 2019 (COVID‐19) has had an unprecedented impact on the overall health and the global economy. Vaccination is currently the most dependable strategy to end the pandemic, despite the slower‐than‐hoped‐for rollout, particularly for low‐to‐middle‐income countries, and the uncertain duration of protection afforded by vaccination. The spike protein of the virus (immunodominant antigen of the virus) is the main target of the approved and candidate SARS‐CoV‐2 vaccines. This protein binds to the ACE2 receptor of the host cell, initiating the entry of the virus into the cell and the chain of subsequent events ending to Acute R…

medicine.medical_specialtyAllergyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)ExacerbationReview ArticleDermatologyallergic reactionsmedicine.disease_causeSARS‐CoV‐2VirusAntigenCOVID‐19PandemicHypersensitivityHumansMedicineIntensive care medicineReview ArticlesCoronavirusbusiness.industryVaccinationCOVID-19cutaneous reactionsmedicine.diseaseVaccinationBNT162b2mRNA VaccinesbusinessJournal of Cosmetic Dermatology
researchProduct

Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization

2022

Abstract Aims Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has had a serious worldwide impact on human health. On December 2020, an immunization campaign with a COVID-19 mRNA vaccine (Comirnaty-BNT162b2 Pfizer-BioNTech) was started in Italy, first targeting healthcare workers (HCWs). This study aims to investigate the antibodies that are response against SARS-CoV-2 vaccine. Methods and Results The kinetics and the persistence of both anti-S1/S2 IgGs and neutralizing antibodies (Nt-Abs) were investigated in 76 HCWs through a 4-month follow-up with multiple testing points starting at the first dose. Temporal analysis of SARS-CoV-2 Abs titre kinetics showed three diff…

Settore MED/07 - Microbiologia E Microbiologia ClinicaVaccines SyntheticCOVID-19 VaccinesSARS-CoV-2VaccinationCOVID-19General Medicineneutralizing antibodies.Settore MED/42 - Igiene Generale E ApplicataAntibodies ViralAntibodies NeutralizingApplied Microbiology and BiotechnologyKineticsItalyhealthcare workerImmunoglobulin GSpike Glycoprotein CoronavirusHumansmRNA Vaccineskinetics of antibodieBNT162 VaccineBiotechnologyJournal of Applied Microbiology
researchProduct

Factors Affecting Hesitancy to mRNA and Viral Vector COVID-19 Vaccines among College Students in Italy

2021

Vaccine hesitancy (VH) may be significant in jeopardizing efforts to mass containment of COVID-19. A cross-sectional survey was carried out on a sample of 2667 Italian college students, before the COVID-19 vaccines became available for this age group (from 7 May to 31 May 2021). An online survey was created to obtain information about socio-demographic, health-related, and psychological factors linked to mRNA and viral vector COVID-19 vaccines. Statistically significant higher VH (30.4%) and vaccine resistance (12.2%) rates were found for viral vector than mRNA COVID-19 vaccines (7.2% and 1.0%, respectively; p < 0.001). Factors related to viral vector VH were partially different from tho…

Agreeablenessmedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Immunologyvaccine hesitancy; COVID-19; mRNA vaccines; viral vector vaccines; college students; ItalyArticleViral vectorOddsDrug DiscoverymedicinePharmacology (medical)Pharmacologybusiness.industryPublic healthcollege studentsRCOVID-19mRNA vaccinesInfectious DiseasesItalyviral vector vaccinesvaccine hesitancyMedicinebusinessDemographyVaccines
researchProduct

Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination li…

2022

Patients with liver diseases, especially those with cirrhosis, have an increased mortality risk when infected by SARS-CoV-2 and therefore anti-SARS-CoV-2 vaccine has been recommended by leading Scientific Associations for all patients with chronic liver diseases. However, previous reports have shown a reduced antibody response following the full course of vaccination in immunosuppressed patients, including liver transplant recipients and several rheumatic diseases. This document, drafted by an expert panel of hepatologists appointed by the Italian Association for the Study of the Liver (AISF), aims to present the updated scientific data on the safety and efficacy of anti-SARS-CoV-2 mRNA vac…

Hepatitis AutoimmuneSettore MED/12 - GastroenterologiaCOVID-19 VaccinesHepatologySARS-CoV-2Liver DiseasesVaccinationGastroenterologyCOVID-19HumansSARS-CoV-2 mRNA vaccines autoimmune hepatitis immunosoppressionDigestive and Liver Disease
researchProduct

Effectiveness of mRNA COVID-19 Vaccination on SARS-CoV-2 Infection and COVID-19 in Sicily over an Eight-Month Period

2022

In order to reduce the spread of SARS-CoV-2 infection and the burden of disease, since 27 December 2020, Sicily has introduced a regional COVID-19 vaccination campaign. This study aimed at estimating the effectiveness of mRNA COVID-19 vaccines on SARS-CoV-2 infections and COVID-19. A retrospective cohort study was carried out on 3,966,976 Sicilian adults aged 18 years or more, who were followed-up from 1 January 2021 to 30 September 2021. The risk of SARS-CoV-2 infection, severe COVID-19, and COVID-19 death or intubation during the study period was compared among vaccinated with two mRNA doses and unvaccinated individuals. Cox regression, adjusted for age and sex, and a joint-point analysis…

PharmacologyCOVID-19; vaccine effectiveness; mRNA vaccinesInfectious DiseasesmRNA vaccineDrug DiscoveryImmunologyCOVID-19Pharmacology (medical)vaccine effectiveness.
researchProduct